New drugs: where did we go wrong and what can we do better?

Abstract

More than half of new drugs entering the German healthcare system have not been shown to add benefit. Beate Wieseler and colleagues argue that international drug development processes and policies are responsible and must be reformed

Cite this work

No public copy is stored for this record, so only the metadata is cited.

Stored only when both papers are in the corpus — 130 citations exist upstream.

Papers that cite the same references — the relational fallback while embeddings are still backfilling.